{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:22:07Z","timestamp":1782516127009,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s11934-018-0819-7","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T04:52:27Z","timestamp":1530593547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers"],"prefix":"10.1007","volume":"19","author":[{"given":"Akshay","family":"Sood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Abdollah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Eilender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zade","family":"Roumayah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Deebajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheen","family":"Alanee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"819_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","volume":"47","author":"JA DiMasi","year":"2016","unstructured":"DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20\u201333.","journal-title":"J Health Econ"},{"key":"819_CR2","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamainternmed.2017.3601","volume":"177","author":"V Prasad","year":"2017","unstructured":"Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177:1569\u201375.","journal-title":"JAMA Intern Med"},{"key":"819_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205\u201314.","journal-title":"Cell"},{"key":"819_CR4","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"819_CR5","first-page":"185","volume":"41","author":"W Alexander","year":"2016","unstructured":"Alexander W. The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge. P & T : Peer Rev J Formul Manag. 2016;41:185\u201391.","journal-title":"P & T : Peer Rev J Formul Manag"},{"key":"819_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","volume":"54","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1\/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev. 2017;54:58\u201367.","journal-title":"Cancer Treat Rev"},{"key":"819_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"819_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.2047-2927.2013.00137.x","volume":"1","author":"TR Saitz","year":"2013","unstructured":"Saitz TR, Serefoglu EC, Trost LW, Thomas R, Hellstrom WJ. The pre-treatment prevalence and types of sexual dysfunction among patients diagnosed with prostate cancer. Andrology. 2013;1:859\u201363.","journal-title":"Andrology"},{"key":"819_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1464-410X.2008.08333.x","volume":"104","author":"MN Aa van der","year":"2009","unstructured":"van der Aa MN, Bekker MD, van der Kwast TH, Essink-Bot ML, Steyerberg EW, Zwarthoff EC, et al. Sexual function of patients under surveillance for bladder cancer. BJU Int. 2009;104:35\u201340.","journal-title":"BJU Int"},{"key":"819_CR10","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1002\/pon.4181","volume":"26","author":"L Wettergren","year":"2017","unstructured":"Wettergren L, Kent EE, Mitchell SA, Zebrack B, Lynch CF, Rubenstein MB, et al. Cancer negatively impacts on sexual function in adolescents and young adults: the AYA HOPE study. Psycho-Oncology. 2017;26:1632\u20139.","journal-title":"Psycho-Oncology"},{"key":"819_CR11","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","volume":"375","author":"JL Donovan","year":"2016","unstructured":"Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375:1425\u201337.","journal-title":"N Engl J Med"},{"key":"819_CR12","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/j.1743-6109.2010.01778.x","volume":"7","author":"RW Lewis","year":"2010","unstructured":"Lewis RW, Fugl-Meyer KS, Corona G, Hayes RD, Laumann EO, Moreira ED Jr, et al. Definitions\/epidemiology\/risk factors for sexual dysfunction. J Sex Med. 2010;7:1598\u2013607.","journal-title":"J Sex Med"},{"key":"819_CR13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1037\/0022-006X.60.4.552","volume":"60","author":"BL Andersen","year":"1992","unstructured":"Andersen BL. Psychological interventions for cancer patients to enhance the quality of life. J Consult Clin Psychol. 1992;60:552\u201368.","journal-title":"J Consult Clin Psychol"},{"key":"819_CR14","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S0140-6736(89)91551-1","volume":"2","author":"D Spiegel","year":"1989","unstructured":"Spiegel D, Bloom JR, Kraemer HC, Gottheil E. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet. 1989;2:888\u201391.","journal-title":"Lancet"},{"key":"819_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/adc.2005.075242","volume":"91","author":"B Edge","year":"2006","unstructured":"Edge B, Holmes D, Makin G. Sperm banking in adolescent cancer patients. Arch Dis Child. 2006;91:149\u201352.","journal-title":"Arch Dis Child"},{"key":"819_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bjc.6600483","volume":"87","author":"FH Blackhall","year":"2002","unstructured":"Blackhall FH, Atkinson AD, Maaya MB, Ryder WD, Horne G, Brison DR, et al. Semen cryopreservation, utilisation and reproductive outcome in men treated for Hodgkin's disease. Br J Cancer. 2002;87:381\u20134.","journal-title":"Br J Cancer"},{"key":"819_CR17","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","volume":"85","author":"TR Mendoza","year":"1999","unstructured":"Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186\u201396.","journal-title":"Cancer"},{"key":"819_CR18","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/cncr.28434","volume":"120","author":"XS Wang","year":"2014","unstructured":"Wang XS, Zhao F, Fisch MJ, O'Mara AM, Cella D, Mendoza TR, et al. Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors. Cancer. 2014;120:425\u201332.","journal-title":"Cancer"},{"key":"819_CR19","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/sj.bjc.6602012","volume":"91","author":"LI Wagner","year":"2004","unstructured":"Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer. 2004;91:822\u20138.","journal-title":"Br J Cancer"},{"key":"819_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","volume":"27","author":"WJ Evans","year":"2008","unstructured":"Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793\u20139.","journal-title":"Clin Nutr"},{"key":"819_CR21","doi-asserted-by":"crossref","unstructured":"Evans W, Smith MR, Morley JE, Barnette KG, Rodriguez D, Steiner MS, et al. Ostarine increases lean body mass and improves physical performance in healthy elderly subjects: implications for cancer cachexia patients. J Clin Oncol 2007;25:9119-.","DOI":"10.1200\/jco.2007.25.18_suppl.9119"},{"key":"819_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","volume":"2","author":"JT Dalton","year":"2011","unstructured":"Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011;2:153\u201361.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"819_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cytogfr.2009.07.004","volume":"20","author":"WK Decker","year":"2009","unstructured":"Decker WK, Safdar A. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley\u2019s legacy revisited. Cytokine Growth Factor Rev. 2009;20:271\u201381.","journal-title":"Cytokine Growth Factor Rev"},{"key":"819_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"819_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med"},{"key":"819_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725\u201333.","journal-title":"N Engl J Med"},{"key":"819_CR27","first-page":"1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunother. Sci. 2013;342:1432\u20133.","journal-title":"Cancer immunother. Sci"},{"key":"819_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","volume":"369","author":"O Hamid","year":"2013","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134\u201344.","journal-title":"N Engl J Med"},{"key":"819_CR29","unstructured":"FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125514s024lbl.pdf ."},{"key":"819_CR30","unstructured":"FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125554s034lbl.pdf ."},{"key":"819_CR31","unstructured":"FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761041lbl.pdf ."},{"key":"819_CR32","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558\u201362.","journal-title":"Nature"},{"key":"819_CR33","unstructured":"FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761078s000lbl.pdf )."},{"key":"819_CR34","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374\u201385.","journal-title":"Lancet Oncol"},{"key":"819_CR35","unstructured":"FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761069s000lbl.pdf ."},{"key":"819_CR36","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol : Off J Am Soc Clin Oncol. 2016;34:3119\u201325.","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"819_CR37","unstructured":"FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125377s073lbl.pdf ."},{"key":"819_CR38","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"819_CR39","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X. Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125:3384\u201391.","journal-title":"J Clin Invest"},{"key":"819_CR40","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1084\/jem.192.7.1015","volume":"192","author":"S Brouard","year":"2000","unstructured":"Brouard S, Otterbein LE, Anrather J, Tobiasch E, Bach FH, Choi AM, et al. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med. 2000;192:1015\u201326.","journal-title":"J Exp Med"},{"key":"819_CR41","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793\u2013800.","journal-title":"Nat Med"},{"key":"819_CR42","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","volume":"56","author":"J Nakanishi","year":"2007","unstructured":"Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol, Immunother : CII. 2007;56:1173\u201382.","journal-title":"Cancer Immunol, Immunother : CII"},{"key":"819_CR43","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","volume":"66","author":"RH Thompson","year":"2006","unstructured":"Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66:3381\u20135.","journal-title":"Cancer Res"},{"key":"819_CR44","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol : Off J Am Soc Clin Oncol. 2010;28:3167\u201375.","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"819_CR45","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/1078-0432.CCR-12-2625","volume":"19","author":"EJ Lipson","year":"2013","unstructured":"Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res : Off J Am Assoc Cancer Res. 2013;19:462\u20138.","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"key":"819_CR46","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","volume":"14","author":"KM Mahoney","year":"2015","unstructured":"Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 2015;14:561\u201384.","journal-title":"Nat Rev Drug Discov"},{"key":"819_CR47","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","volume":"21","author":"JS Weber","year":"2016","unstructured":"Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist. 2016;21:1230\u201340.","journal-title":"Oncologist"},{"key":"819_CR48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","volume":"57","author":"JC Hassel","year":"2017","unstructured":"Hassel JC, Heinzerling L, Aberle J, Bahr O, Eigentler TK, Grimm MO, et al. Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017;57:36\u201349.","journal-title":"Cancer Treat Rev"},{"key":"819_CR49","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian Cancer. J Clin Oncol : Off J Am Soc Clin Oncol. 2015;33:4015\u201322.","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"819_CR50","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"819_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6:230ra45.","journal-title":"Sci Transl Med"},{"key":"819_CR52","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.","journal-title":"Front Immunol"},{"key":"819_CR53","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","volume":"186","author":"P Caturegli","year":"2016","unstructured":"Caturegli P, Di Dalmazi G, Lombardi M, Grosso F, Larman HB, Larman T, et al. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol. 2016;186:3225\u201335.","journal-title":"Am J Pathol"},{"key":"819_CR54","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-13-0499","volume":"21","author":"M Ryder","year":"2014","unstructured":"Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21:371\u201381.","journal-title":"Endocr Relat Cancer"},{"key":"819_CR55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4137\/CMED.S22469","volume":"8","author":"M Mahzari","year":"2015","unstructured":"Mahzari M, Liu D, Arnaout A, Lochnan H. Immune checkpoint inhibitor therapy associated hypophysitis. Clin Med Insights Endocrinol Diabetes. 2015;8:21\u20138.","journal-title":"Clin Med Insights Endocrinol Diabetes"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-018-0819-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-018-0819-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-018-0819-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T23:38:17Z","timestamp":1604533097000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-018-0819-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["819"],"URL":"https:\/\/doi.org\/10.1007\/s11934-018-0819-7","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"3 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Akshay Sood, Daniel Cole, Firas Abdollah, Ben Eilender, Zade Roumayah, Mustafa Deebajah, and Shaheen Alanee each declare no potential conflicts of interest.Ali Dabaja is a section editor forCurrent Urology Reports.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"68"}}